Zobrazeno 1 - 10 of 401 pro vyhledávání: '"Douglas Laird, A."'
1
Akademický článek
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study
Autor: Nicholas C. Turner, A. Douglas Laird, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A. Mina, Judith Balmaña, Peter A. Fasching, Sara A. Hurvitz, Julia F. Hopkins, Lee A. Albacker, Jijumon Chelliserry, Ying Chen, Umberto Conte, Andrew M. Wardley, Mark E. Robson
Publikováno v: npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract These analyses explore the impact of homologous recombination repair gene mutations, including BRCA1/2 mutations and homologous recombination deficiency (HRD), on the efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib i
Externí odkaz: https://doaj.org/article/38e11546389a453baf13464d8594cd8f
Zobrazit plný text záznamu
2
Akademický článek
Drinking water perception and consumption in Canadian subarctic Indigenous communities and the importance for public health
Autor: Mylène Ratelle, Andrew Spring, Brian Douglas Laird, Leon Andrew, Deborah Simmons, Alexa Scully, Kelly Skinner
Publikováno v: FACETS, Vol 7, Iss , Pp 343-359 (2022)
Resource development and climate change are increasing concerns regarding safe water for Indigenous people in Canada. A research study was completed to characterize the consumption of water and beverages prepared with water and identify the perceptio
Externí odkaz: https://doaj.org/article/0cbb26c80abc46a7afa65347c75e2751
Zobrazit plný text záznamu
3
Abstract P2-09-05: Germline BRCA1/2 mutation testing in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC): A real-world study in the Syapse Learning Health Network (LHN)
Autor: Alexander Niyazov, Monika Izano, Colden Johanson, Sheetal Walters, Anna Berry, Bhakti Arondekar, A. Douglas Laird, Lillian Shahied Arruda, Henry Kaplan
Publikováno v: Cancer Research. 82:P2-09
Background: Germline (g)BRCA1/2 mutations represent approximately 5% of metastatic breast cancer. Poly ADP-ribose polymerase inhibitors (PARPi) have shown improved clinical outcomes, a manageable toxicity profile, and favorable patient (pt)-reported
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2f90e15db9d6114ef7f99456bf194654
https://doi.org/10.1158/1538-7445.sabcs21-p2-09-05
Zobrazit plný text záznamu
5
Akademický článek
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
Autor: Daniel J. DeAngelo, Wendy Stock, Anthony S. Stein, Andrei Shustov, Michaela Liedtke, Charles A. Schiffer, Erik Vandendries, Katherine Liau, Revathi Ananthakrishnan, Joseph Boni, A. Douglas Laird, Luke Fostvedt, Hagop M. Kantarjian, Anjali S. Advani
Publikováno v: Blood Advances, Vol 1, Iss 15, Pp 1167-1180 (2017)
Abstract: This study evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of inotuzumab ozogamicin (InO) for CD22-positive relapsed/refractory acute lymphoblastic leukemia. In phase 1, patients received InO 1.2 (n = 3), 1.
Externí odkaz: https://doaj.org/article/75e7d5b654074258b13162642cc5791e
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje